Roivant Sciences (NASDAQ:ROIV) Stock Rating Reaffirmed by Cantor Fitzgerald

Roivant Sciences (NASDAQ:ROIV)‘s stock had its “overweight” rating reiterated by analysts at Cantor Fitzgerald in a note issued to investors on Thursday, Benzinga reports.

Several other equities research analysts have also recently weighed in on the company. Bank of America increased their target price on Roivant Sciences from $12.00 to $12.50 and gave the company a “neutral” rating in a report on Wednesday, September 11th. Piper Sandler increased their price objective on Roivant Sciences from $20.00 to $22.00 and gave the company an “overweight” rating in a research note on Wednesday, July 10th. Finally, HC Wainwright reiterated a “buy” rating and set a $18.00 price target on shares of Roivant Sciences in a report on Thursday. One research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat, Roivant Sciences has an average rating of “Moderate Buy” and a consensus target price of $17.39.

Roivant Sciences Trading Up 0.4 %

ROIV stock opened at $11.97 on Thursday. The company has a market capitalization of $8.84 billion, a PE ratio of 2.37 and a beta of 1.25. The company has a debt-to-equity ratio of 0.05, a quick ratio of 27.91 and a current ratio of 27.91. Roivant Sciences has a one year low of $8.24 and a one year high of $13.24. The company’s 50 day moving average price is $11.46 and its two-hundred day moving average price is $11.06.

Roivant Sciences (NASDAQ:ROIV) last issued its earnings results on Thursday, August 8th. The company reported $0.12 EPS for the quarter, topping analysts’ consensus estimates of ($0.21) by $0.33. Roivant Sciences had a net margin of 2,991.75% and a negative return on equity of 17.23%. The company had revenue of $55.10 million for the quarter, compared to analysts’ expectations of $30.72 million. During the same quarter last year, the company earned ($0.38) EPS. The firm’s revenue was up 155.1% compared to the same quarter last year. As a group, analysts predict that Roivant Sciences will post -1.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Texas Permanent School Fund Corp bought a new stake in shares of Roivant Sciences during the 1st quarter valued at about $3,115,000. American International Group Inc. raised its position in shares of Roivant Sciences by 7,589.5% in the 1st quarter. American International Group Inc. now owns 450,065 shares of the company’s stock worth $4,744,000 after acquiring an additional 444,212 shares in the last quarter. Nordea Investment Management AB purchased a new position in shares of Roivant Sciences in the 1st quarter valued at approximately $2,851,000. Magnetar Financial LLC bought a new stake in shares of Roivant Sciences during the first quarter valued at approximately $1,576,000. Finally, Mutual of America Capital Management LLC grew its stake in Roivant Sciences by 116.8% in the first quarter. Mutual of America Capital Management LLC now owns 325,937 shares of the company’s stock worth $3,435,000 after purchasing an additional 175,574 shares during the period. 64.76% of the stock is owned by hedge funds and other institutional investors.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.